Valproic Acid Prodrug Affects Selective Markers, Augments Doxorubicin Anticancer Activity and Attenuates Its Toxicity in a Murine Model of Aggressive Breast Cancer

We studied the unique inhibitor of the histone deacetylases (HDAC) valproate-valpromide of acyclovir (AN446) that upon metabolic degradation release the HDAC inhibitor (HDACI) valproic acid (VPA). Among the HDAC inhibitors that we have tested, only AN446, and to a lesser extent VPA, synergized with...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarasenko, Nataly, Wilner, Harel Josef, Nudelman, Abraham, Kessler-Icekson, Gania, Rephaeli, Ada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706415/
https://www.ncbi.nlm.nih.gov/pubmed/34959644
http://dx.doi.org/10.3390/ph14121244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706415/
https://www.ncbi.nlm.nih.gov/pubmed/34959644
http://dx.doi.org/10.3390/ph14121244

Ejemplares similares